Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells

Leukemia

Volumn 25, Issue 6, 2011, Pages 1007-1016

  Lewis, T S ^a   McCormick, R S ^a   Stone, I J ^a   Emmerton, K ^a   Mbow, B ^a   Miyamoto, J ^a   Drachman, J G ^a   Grewal, I S ^a   Law, C L ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

BCL 6; dacetuzumab; lymphoma; MAPK; SGN 40; TAp63

Indexed keywords

CARBOPLATIN; CD40 ANTIGEN; CYCLOPHOSPHAMIDE; DACETUZUMAB; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOSENSITIZATION; DRUG MECHANISM; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; LYMPHOMA, NON-HODGKIN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 79958093024     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.21     Document Type: Article

References (50)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262. (Pubitemid 40488631)
2. Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 1993; 53: 2732-2735. (Pubitemid 23180506)
3. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317: 1185-1189. (Pubitemid 17150330)
4. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991; 77: 1057-1063.
5. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92: 3018-3024. (Pubitemid 28492305)
6. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non- Hodgkin's lymphoma. Blood 1997; 90: 4078-4091. (Pubitemid 27484063)
7. Biancone L, Cantaluppi V, Camussi G. CD40-CD154 interaction in experimental and human disease (review). Int J Mol Med 1999; 3: 343-353.
8. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17. (Pubitemid 30046812)
9. Harnett MM. CD40: a growing cytoplasmic tale. Sci STKE 2004; 2004: pe25.
10. Ramesh N, Morio T, Fuleihan R, Worm M, Horner A, Tsitsikov E et al. CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Clin Immunol Immunopathol 1995; 76(3 Part 2): S208-S213.
11. Guzman-Rojas L, Sims-Mourtada JC, Rangel R, Martinez-Valdez H. Life and death within germinal centres: a double-edged sword. Immunology 2002; 107: 167-175. (Pubitemid 35279042)
12. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083-1088. (Pubitemid 46424046)
13. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756. (Pubitemid 41070815)
14. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200-2206. (Pubitemid 30108780)
15. Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787-2794. (Pubitemid 24142707)
16. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603-3613. (Pubitemid 46844778)
17. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14(Suppl 1): i5-10.
18. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13. (Pubitemid 36222071)
19. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331-8338. (Pubitemid 41330598)
20. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009; 100: 113-117.
21. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOPresistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956. (Pubitemid 32110441)
22. Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR et al. BCL-6 expression during B-cell activation. Blood 1996; 87: 5257-5268. (Pubitemid 26189869)
23. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12: 280-292. (Pubitemid 47333420)
24. Jardin F, Ruminy P, Bastard C, Tilly H. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol (Paris) 2007; 55: 73-83. (Pubitemid 46216617)
25. Niu H, Ye BH, Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998; 12: 1953-1961. (Pubitemid 28323870)
26. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173: 1158-1165. (Pubitemid 38924291)
27. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNAdamage sensor ATR. Nat Immunol 2007; 8: 705-714. (Pubitemid 46965346)
28. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635-639. (Pubitemid 39626271)
29. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclindependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6: 1054-1060. (Pubitemid 41486191)
30. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006; 108: 3450-3457.
31. Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R et al. CD74 induces TAp63 expression leading to B-cell survival. Blood 2007; 110: 4303-4311. (Pubitemid 351377795)
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
33. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 2005; 24: 2458-2471. (Pubitemid 41032596)
34. Kelly KF, Daniel JM. POZ for effectFPOZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006; 16: 578-587. (Pubitemid 44636217)
35. Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci USA 2004; 101: 14198-14203. (Pubitemid 39305053)
36. Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7: 445-455. (Pubitemid 40719128)
37. Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009; 113: 3397-3405.
38. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009; 15: 1369-1376.
39. Burington B, Yue P, Shi X, Advani R, Yu N, Lau J et al. CD40 Pathway activation status predicts response to CD40 targeted therapy in diffuse large B cell lymphoma. Sci Transl Med 2011 (in press).
40. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-185.
41. Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol 1997; 17: 1947-1958. (Pubitemid 27133279)
42. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324-335.
43. Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005; 202: 1471-1476. (Pubitemid 41746593)
44. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62. (Pubitemid 34874618)
45. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003; 4: 321-329. (Pubitemid 36432313)
46. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi- Tsuda E, Gravallese EM et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001; 412: 300-307. (Pubitemid 32691837)
47. Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol 2000; 20: 8684-8695. (Pubitemid 32245902)
48. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316. (Pubitemid 128379271)
49. Li Y, Zhou Z, Chen C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitinmediated proteasomal degradation and regulates apoptosis. Cell Death Differ 2008; 15: 1941-1951.
50. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-4213. (Pubitemid 43801342)